Western blot analysis of the inhibitor-treated cells was performed using a standardized protocol [22 (link)]. The primary human antibodies used in these analyses included NF-κB (p65), Smo, p53, p21, Nestin and β-actin (Santacruz, CA), IκBα, phospho-IκBα, phospho-NF-κB (p65), Bcl-2, S6K, phospho-S6K, 4E-BP1, phospho-4E-BP1, PLK1 and N-Myc (Cell Signaling Technology, MA) and cyclin D1, Bcl-2, and CD133 (BD Biosciences, CA). Immunoreactivity was detected using appropriate peroxidase-conjugated secondary antibodies (Santacruz, CA) and visualized using an enhanced chemiluminescence (ECL) detection system (Pierce, IL).
Free full text: Click here